NEW YORK (GenomeWeb News) – Investment bank JP Morgan has upgraded Beckman Coulter's stock to "overweight" from "neutral," due to the firm's long-range earnings forecast.

In mid-December, Beckman Coulter set a preliminary 2010 guidance for adjusted earnings per share of between $4.40 and $4.55, which was just below analysts' consensus estimate of $4.56.

JP Morgan also set a 12-month price target on the stock of $75.

In early Monday trade on the New York Stock Exchange, shares of Beckman Coulter were up around 2 percent at $67.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.